ReportWire

Tag: ZBH

  • Atria Wealth Solutions Inc. Has $2.31 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

    Atria Wealth Solutions Inc. Has $2.31 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

    [ad_1]

    Atria Wealth Solutions Inc. raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 5.9% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 20,566 shares of the medical equipment provider’s stock after acquiring an additional 1,144 shares during the period. Atria Wealth Solutions Inc.’s holdings in Zimmer Biomet were worth $2,312,000 as of its most recent filing with the SEC.

    Other institutional investors have also recently bought and sold shares of the company. Brown Brothers Harriman & Co. increased its stake in shares of Zimmer Biomet by 4.0% in the second quarter. Brown Brothers Harriman & Co. now owns 2,063 shares of the medical equipment provider’s stock valued at $300,000 after buying an additional 80 shares during the period. Private Trust Co. NA increased its stake in shares of Zimmer Biomet by 8.1% in the second quarter. Private Trust Co. NA now owns 1,105 shares of the medical equipment provider’s stock valued at $161,000 after buying an additional 83 shares during the period. Glenview Trust Co increased its stake in shares of Zimmer Biomet by 1.5% in the second quarter. Glenview Trust Co now owns 5,564 shares of the medical equipment provider’s stock valued at $810,000 after buying an additional 84 shares during the period. Bradley Foster & Sargent Inc. CT increased its stake in shares of Zimmer Biomet by 1.3% in the fourth quarter. Bradley Foster & Sargent Inc. CT now owns 6,452 shares of the medical equipment provider’s stock valued at $823,000 after buying an additional 85 shares during the period. Finally, Parallel Advisors LLC increased its stake in shares of Zimmer Biomet by 5.7% in the second quarter. Parallel Advisors LLC now owns 1,583 shares of the medical equipment provider’s stock valued at $231,000 after buying an additional 85 shares during the period. Institutional investors own 87.48% of the company’s stock.

    Zimmer Biomet Stock Down 0.2 %

    ZBH stock opened at $122.80 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $149.25. The company has a quick ratio of 0.99, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average is $121.39 and its 200-day moving average is $117.68. The firm has a market capitalization of $25.66 billion, a PE ratio of 25.11, a P/E/G ratio of 2.24 and a beta of 1.03.

    Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same quarter last year, the company earned $1.88 earnings per share. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current fiscal year.

    Zimmer Biomet Announces Dividend

    The business also recently announced a quarterly dividend, which was paid on Wednesday, January 31st. Stockholders of record on Wednesday, December 27th were issued a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, December 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.78%. Zimmer Biomet’s dividend payout ratio is presently 19.63%.

    Wall Street Analyst Weigh In

    Several brokerages have recently weighed in on ZBH. Royal Bank of Canada reissued an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday. JPMorgan Chase & Co. raised their target price on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday. Evercore ISI cut Zimmer Biomet from an “outperform” rating to an “inline” rating and decreased their target price for the stock from $135.00 to $125.00 in a research note on Thursday, January 4th. Truist Financial raised their target price on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research note on Friday. Finally, TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday. Two analysts have rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $138.11.

    Get Our Latest Analysis on ZBH

    Zimmer Biomet Company Profile

    (Free Report)

    Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

    Featured Articles

    Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).

    Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

    Receive News & Ratings for Zimmer Biomet Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zimmer Biomet and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • CDC shoots down false claims it will mandate COVID-19 vaccines for schoolchildren, saying states make that decision

    CDC shoots down false claims it will mandate COVID-19 vaccines for schoolchildren, saying states make that decision

    [ad_1]

    The Centers for Disease Control and Prevention has refuted claims that it’s planning to add the COVID-19 vaccine to immunization schedules for schoolchildren, saying that the authority for that decision lies with states and other local entities.

    The false claim spread after it was shared by Fox News host Tucker Carlson in a tweet this week, as the Associated Press reported. 

    Carlson tweeted that the agency would make the vaccine mandatory in order for children to attend school, a claim the CDC quickly shot down. While an advisory committee to the CDC voted to recommend that the vaccine be added to immunization schedules, the CDC “only makes recommendations for use of vaccines, while school-entry vaccination requirements are determined by state or local jurisdictions,” CDC spokeswoman Kate Grusich told the AP.

    Grusich explained that the action was meant to streamline clinical guidance for healthcare providers by adding COVID-19 vaccines to a single list of all currently licensed, authorized and routinely recommended vaccines.

    “It’s important to note that there are no changes in COVID-19 vaccine policy,” she said.

    The news comes as U.S. known cases of COVID are continuing to ease and now stand at their lowest level since mid-April, although the true tally is likely higher given how many people overall are testing at home, where data are not being collected.

    The daily average for new cases stood at 38,077 on Thursday, according to a New York Times tracker, down 8% from two weeks ago. Cases are currently rising in 14 states, as well as Washington, D.C., and Puerto Rico.

    The daily average for hospitalizations was down 2% to 26,669, although hospitalizations are rising in almost all northeastern states as cold weather arrives. The daily average for deaths was down 7% to 360.

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Pfizer
    PFE,
    +4.42%
    is planning to sell the COVID vaccine it developed with German partner BioNTech
    BNTX,
    +9.88%
    for $110 -$130 a dose once the U.S. market for COVID-19 shots becomes commercial, likely in the first quarter of next year, MarketWatch’s Jaimy Lee reported. Pfizer and BioNTech are currently paid $30.50 per vaccine dose by the U.S. government, which contracted with the companies, as well as with other vaccine makers like Moderna
    MRNA,
    +9.07%
    and Novavax
    NVAX,
    +11.35%    ,
    and then made the COVID-19 shots available at no cost to people in the U.S. during the public-health emergency. The emergency declaration in the U.S. isn’t expected to be renewed next year, which will lead to the formation of an official commercial market for COVID-19 vaccines, tests and treatments. 

    • Johnson & Johnson
    JNJ,
    +1.91%
    said the volume of surgical procedures is returning to prepandemic levels in many parts of the world, a trend that cheered Wall Street and could bode well for other medical-technology heavyweights like Stryker Corp.
    SYK,
    +0.57%
    and Zimmer Biomet Holdings
    ZBH,
    +0.18%    .
    J&J, which reported earnings this week, said its medical-technology business had a “strong September,” with U.S. sales of hip and knee implants and other surgical devices rising 7.7% to $3.3 billion in the third quarter of the year. “We are seeing procedures recovering,” Ashley McEvoy, worldwide chair of J&J’s MedTech business, told investors during this week’s earnings call. “In the U.S., we started to see surgical procedures tick up, predominantly at the latter part of the quarter.”

    The new bivalent vaccine might be the first step in developing annual COVID shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to COVID could be challenging. Illustration: Ryan Trefes

    • “As China’s ruling Communist Party holds a congress this week, many Beijing residents are focused on an issue not on the formal agenda: Will the end of the meeting bring an easing of China’s at times draconian ‘zero-COVID’ policies that are disrupting lives and the economy?” the AP reported. It appears to be wishful thinking. As the world moves to a postpandemic lifestyle, many across China have resigned themselves to lining up several times a week for COVID tests, restrictions on travel to other regions and the ever-present possibility of a community lockdown.

    • Fantasy Fest, a 10-day annual party, is kicking off in Key West, Fla., on Friday, with a full slate of events for the first time since the pandemic started, the AP reported. “Due to the COVID pandemic, this will be the first full Fantasy Fest since 2019,” the festival’s board chair, Steve Robbins, said. “So I know our guests and staff are excited about getting back to the real Fantasy Fest.” Dozens of themed events are set for the festival, including a nighttime parade Oct. 29 featuring floats and elaborately costumed marching groups. Participants are encouraged to draw costume ideas from the festival’s theme, “Cult Classics & Cartoon Chaos,” and to portray characters inspired by favorite cartoons and television or film productions with a cult following.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 626.9 million on Friday, while the death toll rose above 6.57 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 97.2 million cases and 1,067,190 fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 226.5 million people living in the U.S., equal to 68.2% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 111.4 million have had a booster, equal to 49.1% of the vaccinated population, and 26.8 million of those who are eligible for a second booster have had one, equal to 40.6% of those who received a first booster.

    The CDC reports that some 19.4 million people have had a dose of the updated bivalent booster that targets omicron and its subvariants along with the original virus.

    [ad_2]

    Source link